Real-World Effectiveness and Safety of Mepolizumab in Severe Eosinophilic Asthma: Insights From the Korean Severe Asthma Registry (KoSAR)

• DOI: 10.4168/aair.2025.17.3.384
• Publication Date: 2025-05-22T07:57:32Z
• Authors: So-Young Park; Daegeun Lee; Joo-Hee Kim; Youngsoo Lee; Ga-Young Ban; Da Woon Sim; Jae-Woo Kwon; So Ri Kim; Woo-Jung Song; Heung-Woo Park; Yoon-Seok Chang; Young-Il Koh; Byung-Jae Lee; Hae-Sim Park; You Sook Cho; Sang-Heon Kim

Mepolizumab, an interleukin-5 antagonist, is globally recognized for its efficacy in randomized controlled trials the treatment of severe eosinophilic asthma. The present study explored real-world effectiveness and safety a Korean cohort, filling critical gap current research. This multi-center retrospective used data from Severe Asthma Registry, involving 67 patients treated with mepolizumab uncontrolled asthma between September 2017 July 2022. We assessed effects on acute exacerbations, oral corticosteroid (OCS) maintenance dose, lung function, quality life. notable findings included marked reduction proportion experiencing 73.0% reporting no exacerbations during 6-month period. At baseline, 31.8% had reported over prior 12 months. OCS doses also decreased substantially, only 3.2% requiring after 6 Additionally, there was improvement function. No adverse reactions were this study, highlighting mepolizumab. confirmed that reduced use, additional improvements seen control, patient-reported These support broader applications reinforce need further research to optimize strategies. Despite certain limitations, such as small sample size design, significantly contributes understanding